Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y RosenMelissa L JohnsonSarah E CliffordRomel SomwarJennifer F KheraniJieun SonArrien A BertramMonika A DavareEric GladstoneElena V IvanovaDahlia N HenryElaine M KelleyMika LinMarina S D MilanBinoj C NairElizabeth A OlekJenna E ScanlonMorana VojnicKevin EbataJaclyn F HechtmanBob T LiLynette M ShollBarry S TaylorMarc LadanyiPasi A JänneS Michael RothenbergAlexander E DrilonGeoffrey R OxnardPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Through the use of SPPs, we were able to offer combination therapy targeting MET-amplified resistance identified on the first-in-human study of selpercatinib. These data suggest that MET dependence is a recurring and potentially targetable mechanism of resistance to selective RET inhibition in advanced NSCLC.